Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06002607

Shorter Versus Extended Course of Antibiotic Therapy for Necrotizing Soft Tissue Infections

Necrotizing soft tissue infection (NSTI) is a devastating disease that results in a high rate of in-hospital complications and despite advances in critical care, wound care, and early intervention, NSTI continues to be associated with a mortality rate of nearly 30%. The antibiotics used in this treatment are Clindamycin, Vancomycin, Piperacillin Tazobactam; these antibiotics may be administered combined or individually, based on individualized patient treatment. Although one of the tenets of management for NSTI is early broad-spectrum intravenous antibiotics (listed above), the duration of antibiotics needed is not well defined. Currently, there exists wide variation in the duration of antibiotics for NSTI ranging between 2-16 days. The objective of this study is to evaluate the safety of a shorter course of antibiotics hypothesizing that a short duration of antibiotics for 48-hours after source-control is achieved will have similar risk of morbidity and mortality compared to a 7-day course of antibiotics post source control. A second aim of this study will be to identify if serum procalcitonin levels/ratio correspond to resolution of systemic infection in patients with NSTI.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University of California Irvine Medical Center

Orange, California, 92868, United States

Location status: Recruiting

Location contact

Areg Grigorian, MD

CONTACT

[email protected]

8184389093

Areg Grigorian, MD

PRINCIPAL_INVESTIGATOR

Claudia A Alvarez, MD

SUB_INVESTIGATOR

Jeffry Nahmias, MD

CONTACT

[email protected]

9493073035

Jeffry Nahmias, MD

SUB_INVESTIGATOR

Lanny L Hsieh, MD

SUB_INVESTIGATOR

Negaar Aryan, MD

SUB_INVESTIGATOR

Sebastian Schubl, MD

SUB_INVESTIGATOR

Steven E Atallah, PharmD

SUB_INVESTIGATOR

About this study

The objective of this study is to evaluate the safety of a shorter course of antibiotics hypothesizing that a short duration of antibiotics for 48-hours after source-control is achieved will have similar risk of morbidity and mortality compared to a 7-day course of antibiotics post source control. The proposed shortened duration is considered within standard of care as the IDSA suggests 48-72 hours of antibiotics after source control, however this was due mostly to expert opinion until a recent single-center study using historical controls demonstrated a 48-hour duration of antibiotics to be safe. A second aim of this study will be to identify if serum procalcitonin levels/ratio correspond to resolution of systemic infection in patients with NSTI. This pilot study may help limit use of antibiotics which are associated with both cost and significant adverse events including antimicrobial resistance and clostridium difficile infections. In addition, the data would support grant submission of a larger, multi-center study with sufficient power to demonstrate the safety profile and potential benefits of a shorter duration of antibiotics, which has been shown to be beneficial in previous large surgical infection studies.

Specific Aims:

Aim#1: Establish the safety of an abbreviated course (48 hours after source control) compared to a prolonged (7 days after source control) course of antibiotics in terms of in-hospital mortality.

Aim#2: Compare the incidence of hospital length of stay and in-hospital complications including unplanned return to the operating room, ventilator days, and antibiotic associated complications (e.g., clostridium difficile infection) in the two comparison groups: abbreviated (48-hours) and prolonged antibiotics (7-days) after source control.

Aim#3: Identify a critical threshold of biochemical procalcitonin or a % decrease in procalcitonin from the initial procalcitonin obtained upon admission that suggests resolution of systemic infection in patients with NSTI. This will be done by obtaining a serum procalcitonin upon admission and daily for up to 7 days from admission or once source control has been achieved.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patients 18 years of age or older with all following criteria:
  • Presenting to the Emergency Department with history, exam and/or imaging concerning NSTI, AND
  • Patients who undergo consultation by the Emergency General Surgery service, AND
  • Patients included must have skin or soft tissue findings consistent with NSTI (erythema, crepitus, or pain out of proportion to exam), AND
  • Systemic signs of infection including fever (temperature >38.0°C) or leukocytosis (≥11,000 peripheral white cells per cubic millimeter), AND
  • Patients who undergo excisional debridement and/or amputation to achieve source control.

Exclusion criteria

  • Pregnant patients
  • Prisoners
  • Patients with bacteremia upon admission
  • Patients unable to provide consent (including no legally authorized representative)

Treatment and study plan

Antibiotic duration (short course)

Other

The patient will be enrolled in a 48-hour course of antibiotics.

Antibiotic duration (extended course)

Other

The patient will be enrolled in a 7 day course of antibiotics.

Primary outcomes

  1. Safety of the antibiotic course duration

    Time frame: Through study completion, an average of 1 year

    In-hospital complications

  2. Mortality rate

    Time frame: Through study completion, an average of 1 year

    In-hospital mortality

Secondary outcomes

  1. Age

    Time frame: Baseline, pre-intervention/procedure/surgery

    Age in years

  2. Sex

    Time frame: Baseline, pre-intervention/procedure/surgery

    Sex (male/female)

  3. BMI (body mass index)

    Time frame: Baseline, pre-intervention/procedure/surgery

    Body mass index (weight and height will be combined to report BMI in kg/m^2)

  4. Blood Pressure

    Time frame: Baseline, pre-intervention/procedure/surgery

    Blood Pressure (mmHg)

  5. Heart Rate

    Time frame: Baseline, pre-intervention/procedure/surgery

    Heart rate (beats/minute)

  6. Respiratory rate

    Time frame: Baseline, pre-intervention/procedure/surgery

    Respiratory rate (breaths/minute)

  7. Temperature

    Time frame: Baseline, pre-intervention/procedure/surgery

    Temperature (Fahrenheit)

  8. Comorbidities

    Time frame: Baseline, pre-intervention/procedure/surgery

    Comorbidities (e.g., diabetes, hypertension, cirrhosis, chronic kidney disease, etc.)

  9. Transfusion requirements

    Time frame: Baseline, pre-intervention/procedure/surgery

    Number of Packed Red Blood Cells transfused measured in milliliters

  10. NSTI location

    Time frame: Baseline, pre-intervention/procedure/surgery

    Anatomical location of soft tissue infection

  11. Operations

    Time frame: Through study completion, an average of 1 year

    Number of surgical procedures

  12. Serum concentration of procalcitonin

    Time frame: Upon admission and daily blood sample for 7 days

    Procalcitonin ng/mL

  13. Serum concentration of white blood cell

    Time frame: Through study completion, an average of 1 year

    White blood cell count cells per microliter (cells/μL)

  14. Serum concentration of hemoglobin

    Time frame: Through study completion, an average of 1 year

    Hemoglobin grams/deciliter

  15. Serum concentration of sodium

    Time frame: Through study completion, an average of 1 year

    Sodium millimoles per liter (mmol/L)

  16. Serum concentration of C-reactive protein

    Time frame: Through study completion, an average of 1 year

    C-reactive protein milligrams/liter

  17. Serum concentration of glucose

    Time frame: Through study completion, an average of 1 year

    Glucose milligrams/deciliter

  18. Serum concentration of creatinine

    Time frame: Through study completion, an average of 1 year

    Creatinine milligram/deciliter

  19. Total hospital length of stay

    Time frame: Through study completion, an average of 1 year

    Total days of hospital stay

  20. Total intensive care unit (ICU)

    Time frame: Through study completion, an average of 1 year

    Total days of ICU stay

  21. Total ventilator days

    Time frame: Through study completion, an average of 1 year

    Total days of ventilation support for the patient

Study contacts

Contact information is provided by the study sponsor or research team.

Areg Grigorian, MD

CONTACT

[email protected]

8184389093

Jeffry Nahmias, MD

CONTACT

[email protected]

9493073035

Sponsors and collaborators

Lead sponsor

University of California, Irvine

Other

Registry information

Official study title

Pilot Randomized Controlled Trial of Shorter Versus Extended Course of Antibiotic Therapy for Necrotizing Soft Tissue Infections

Important dates

Study start
2023
Primary completion
2026
Study completion
2026
First posted
Aug 21, 2023
Registry last updated
Feb 10, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.